Grant from CIRM for the Phase IIb trial of SB623 in chronic-stage ischemic stroke
First written in FY2018-Q2. 6 of 10 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「② Total grant proceeds received: US$18.9 million」
The total CIRM grant of US$18.9 million and the payment conditions linked to patient enrollment, follow-up and the final report have been reconfirmed. - FY2020AdvancedAnnual report
「② Total grant proceeds received: US$18.9 million」
The conditions for receiving a total of US$18.9 million under the CIRM grant have been clarified, with payments linked to contract execution, 65%, 85% and 100% patient enrollment, completion of follow-up, and the final report. - FY2020-Q3RestatedAnnual report
「The company recorded ¥489 million in non-operating income attributable to grants from the California Institute for Regenerative Medicine (CIRM).」
The CIRM grant for the SB623 Phase IIb trial in chronic ischemic stroke was recorded as ¥489 million in non-operating income for the nine-month consolidated cumulative period of the third quarter. - FY2020-Q1RestatedAnnual report
「In addition, as a result of recording ¥290 million in non-operating income and ¥237 million in foreign exchange gains attributable to grants from the California Institute for Regenerative Medicine (CIRM)」
The CIRM grant for the SB623 Phase IIb trial in chronic ischemic stroke was recorded as ¥290 million in non-operating income for the quarter. - FY2019RestatedAnnual report
「The company recorded ¥927 million in non-operating income attributable to grants from the California Institute for Regenerative Medicine (CIRM).」
The CIRM grant for the SB623 Phase IIb trial in chronic ischemic stroke was recorded as ¥927 million in non-operating income for the fiscal year. - FY2019-Q3RestatedAnnual report
「In addition, as a result of recording ¥675 million in non-operating income and ¥325 million in foreign exchange gains attributable to grants from the California Institute for Regenerative Medicine (CIRM), the ordinary loss was ¥1,547 million, compared with an ordinary loss of ¥3,164 million in the same period of the previous year.」
The company recorded ¥675 million in non-operating income related to the CIRM grant, reflecting the grant for the SB623 Phase IIb trial in chronic ischemic stroke in revenue for the quarter. - FY2019-Q2RestatedAnnual report
「In addition, as a result of recording ¥472 million in non-operating income and ¥165 million in foreign exchange gains attributable to grants from the California Institute for Regenerative Medicine (CIRM), the ordinary loss was ¥1,040 million, compared with an ordinary loss of ¥2,282 million in the same period of the previous year.」
The company recorded ¥472 million in non-operating income related to the CIRM grant, reflecting the grant for the SB623 Phase IIb trial in chronic ischemic stroke in revenue for the quarter. - FY2018AdvancedAnnual report
「Of the US$20 million grant, we have already received a total of US$18 million, comprising US$4.5 million upon execution of the agreement with CIRM, US$4.9 million upon achievement of 65% patient enrollment, US$4.1 million upon achievement of 85% enrollment, and US$4.5 million upon completion of enrollment of all patients.」
Receipt of the CIRM grant has progressed to a total of US$18 million upon satisfaction of the conditions relating to contract execution and 65%, 85% and 100% patient enrollment. - FY2018-Q3AdvancedAnnual report
「As of the filing date, we had already received $9.4 million of the $20 million grant, comprising $4.5 million for the execution of the agreement with CIRM relating to the grant and $4.9 million upon achieving 65% patient enrollment. Of this amount, $4.5 million has been recognized as ¥513 million in advances received under current liabilities.」
Of the US$20 million CIRM grant, US$9.4 million in total was received upon contract execution and achievement of 65% patient enrollment. The mechanism under which the grant is received in multiple installments linked to specified development milestones has also been clarified. - FY2018-Q2First statedAnnual report
「In June 2017, the company obtained a grant totaling US$20 million from the California Institute for Regenerative Medicine (CIRM) for the Phase IIb clinical trial of SB623 in chronic ischemic stroke.」
The grant totaling US$20 million from CIRM for the Phase IIb clinical trial of SB623 in chronic ischemic stroke was disclosed for the first time.